

Substitute Form PTO-1449  
(Modified)U.S. Department of Commerce  
Patent and Trademark Office

Attorney's Docket No.

06501-083001

Application No.

09/891,053

**RECEIVED****Information Disclosure Statement  
by Applicant**

(Use several sheets if necessary)

Applicant

Hiraku Itadani et al.

JUL 16 2002

Filing Date

June 25, 2001

Group Art Unit

1635

TECH CENTER 1600/29

**U.S. Patent Documents**

Examiner Initial	Desig. ID	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA						
	AB						

**Foreign Patent Documents or Published Foreign Patent Applications**


Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AC							
	AD							

**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
	AE	GenBank Accession No. R87217, October 10, 1995
	AF	EMBL Accession No. AA859887, March 14, 1998
	AG	Leurs et al., "The histamine H <sub>3</sub> -receptor: A target for developing new drugs," <i>Prog Drug Res</i> 39:127-65, 1992
	AH	Leurs et al., "Therapeutic potential of histamine H <sub>3</sub> receptor agonists and antagonists", <i>Trends Pharmacol Sci</i> , 19(5):177-83, 1998
	AI	Cherifi et al., "Purification of a Histamine H <sub>3</sub> Receptor Negatively coupled to Phosphoinositide Turnover in the Human Gastric Cell Line HGT1", <i>J Biol Chem</i> , 267(35):25315-20
	AJ	Laitinen et al., "Guanosine 5'-( $\gamma$ -[ <sup>35</sup> S]Thio)triphosphate Autoradiography Allows Selective Detection of Histamine H <sub>3</sub> Receptor-Dependent G Protein Activation in Rat Brain Tissue Sections", <i>J Neurochem</i> , 71(2):808-16
	AK	Arrang et al., "Auto-inhibition of brain histamine release mediated by a novel class (H <sub>3</sub> ) of histamine receptor", <i>Nature</i> , 302(5911):832-7

**COPY OF PAPERS  
ORIGINALLY FILED**

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Sheet 1 of 1

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 06501-083001	Application No. 09/891,053
		Applicant Hiraku Itadani <i>et al.</i>	
		Filing Date June 25, 2001	Group Art Unit 1635

**Information Disclosure Statement  
by Applicant**  
(Use several sheets if necessary)

(37 CFR §1.98(b))

**U.S. Patent Documents**

Examiner Initial	Desig. ID	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date If Appropriate
<i>2</i>	AA	US 4,767,778	08/30/88	Arrang <i>et al.</i>	<i>—</i>	<i>—</i>	
<i>2</i>	AB	US 5,342,960	08/30/94	Garbarg <i>et al.</i>	<i>—</i>	<i>—</i>	
<i>—</i>	AC	US 5,882,893	03/16/99	Goodearl	<i>—</i>	<i>—</i>	

**Foreign Patent Documents or Published Foreign Patent Applications**

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
<i>a</i>	AD	WO 91/17146	11/14/91	WIPO	<i>—</i>	<i>—</i>		
<i>2</i>	AE	WO 99/28470	06/10/99	WIPO	<i>—</i>	<i>—</i>		
<i>9</i>	AF	WO 99/33978	07/08/99	WIPO	<i>—</i>	<i>—</i>	See Below	<i>X</i>
<i>2</i>	AG	WO 00/20011	04/13/00	WIPO	<i>—</i>	<i>—</i>		

**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
<i>2</i>	AH	Lovenberg <i>et al.</i> , "Cloning and Functional Expression of the Human Histamine H <sub>2</sub> Receptor" <i>Molecular Pharmacology</i> 55:1101-1107, 1999.
<i>2</i>	AI	English description of WO 99/33978
	AJ	
	AK	

**RECEIVED**

MAR 06 2002

TECH CENTER 1600 2900

Examiner Signature <i>[Signature]</i>	Date Considered <i>2-10-03</i>
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Substitute Disclosure Form (PTO-1449)